Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

Amgen

Status and phase

Completed

Phase 1

Conditions

Osteoporosis

Treatments

Biological: Denosumab

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03822078

20030164

Details and patient eligibility

About

The primary objective was to evaluate the safety and tolerability of denosumab (AMG 162) after a single subcutaneous administration in Japanese postmenopausal women.

Enrollment

45 patients

Sex

Volunteers

No Healthy Volunteers

Inclusion criteria

ambulatory women between the ages of 40 and 64 years, inclusive
postmenopausal, defined as amenorrheic for at least 24 months
clinically acceptable physical exam
clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) within normal limits or clinically acceptable to the investigator/sponsor at the time of screening with the exception of aspartate transaminase (AST) and alkaline phosphatase (ALT), which must be < 1.25 times the upper limit of normal, or gamma-glutamyl transpeptidase (GGT), which must be < 1.5 times the upper limit of normal
normal or clinically acceptable electrocardiogram (ECG) (12-lead reporting ventricular rate and PR, QRS, QT, and QTc intervals)
body mass index between 17 and 27
willing to sign an approved informed consent form before any study-specific assessments and oral consultations are performed

Exclusion criteria

administration of medications within 6 months before investigational product administration that are known to effect bone metabolism, including but not limited to the following: calcitonin, parathyroid hormone (or any derivative), supplemental vitamin D (> 1000 IU/day), glucocorticosteroids (inhaled or topical corticosteroids administered more than 2 weeks before the date of informed consent were allowed), anabolic steroids, calcitriol and available analogues, diuretics
administration of the following medications within 12 months before study drug administration: bisphosphonates, fluoride for osteoporosis
diagnosed with any condition that affects bone metabolism
greatly differing levels of physical activity compared with the 6 months before investigational product administration or constant levels of intense physical activities
routine alcohol intake of ≥ 2 drinks/day, on average, within 6 months of investigational product administration
known sensitivity to any drugs
positive test results for hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus antigen/antibody, syphilis
receiving or received any investigational drug (or was currently using an investigational device) within 4 months before receiving investigational product
donated any amount of blood within 16 weeks, or over 400 mL (Note: not 400 mL but 200 mL, for the subjects who were to be enrolled into cohorts 4 or 5) within 1 year of the start day of screening
subject had previously entered this study
any other condition that might have reduced the chance of obtaining data (eg, known poor compliance) required by the protocol or that might have compromised the ability to give truly informed consent